Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	5.6M 0 4.88M 4.52M 4.23M 7.94M 528M 7.99M 53.66M 20.79M 260M 21.02M 20.57M 903M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.6M 0 4.88M 4.52M 4.23M 7.94M 528M 7.99M 53.66M 20.79M 260M 21.02M 20.57M 903M	EV / Sales 2026 *	3.77x	EV / Sales 2027 *	2.15x
Free-Float	82.9%	Yield 2026 *	-	Yield 2027 *	-

06-02	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
05-20	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-20	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
05-20	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
05-19	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
04-24	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
04-03	Evogene reports receipt of Nasdaq minimum bid price notification	RE
04-03	Evogene Gets Nasdaq Minimum Bid Price Notification	MT
03-05	Evogene Ltd., Q4 2025 Earnings Call, Mar 05, 2026
03-05	Evogene Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-25	Evogene substantially completed divestment of non-core subsidiaries	RE
02-17	Evogene Ltd. and Queensland University of Technology Announce A Collaboration to Advance AI-Driven Cancer Therapeutics	CI
02-11	Evogene, Systasy and LMU University Hospital Munich announce a collaboration to develop therapies for inflammatory diseases	RE

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
18/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
29/07/21	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
01/12/20	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

06-02	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
05-20	Evogene : Q1 2026 Consolidated Financial Statements	PU
05-20	Evogene: Q1 Earnings Snapshot	AQ
05-20	Evogene Reports First Quarter 2026 Financial Results	PR
05-12	Evogene to Present at the 24th Schrödinger European User Group Meeting	PR

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Evogene Ltd Stock TEL AVIV STOCK EXCHANGE

Stocks

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd

Latest news : Evogene Ltd

Last Transcript: Evogene Ltd

Analysts' recommendations: Evogene Ltd

Press Releases: Evogene Ltd

News in other languages: Evogene Ltd

Quotes and Performance

Managers and Directors: Evogene Ltd

Other Biotechnology & Medical Research

Financials

Company Profile

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD	-0.43%	-5.52%	-	-	5.6M
LONZA GROUP AG	+0.34%	+1.09%	-10.80%	-5.05%	43.13B
REVOLUTION MEDICINES, INC.	+1.09%	+3.27%	+312.81%	+561.95%	34.65B
BEONE MEDICINES AG	+0.90%	+1.88%	+6.11%	+46.97%	30.03B
IQVIA HOLDINGS INC.	-1.65%	-7.26%	+6.62%	-22.55%	28B
CELLTRION, INC.	-1.06%	-2.60%	+9.08%	+21.51%	24.45B
ASCENDIS PHARMA A/S	+0.76%	+4.49%	-	-	14.34B
MEDPACE HOLDINGS, INC.	-2.10%	-3.40%	+46.31%	+101.06%	13.14B
EUROFINS SCIENTIFIC SE	+1.54%	+0.16%	+6.65%	+8.89%	12.53B
IONIS PHARMACEUTICALS, INC.	+2.22%	+2.15%	+100.56%	+83.37%	12.25B
Average	+0.17%	+0.65%	+59.67%	+99.52%	23.61B
Weighted average by Cap.	+0.22%	+1.19%	+65.03%	+116.15%

	2026 *	2027 *
Net sales	1.48M 0 1.29M 1.2M 1.12M 2.1M 140M 2.12M 14.22M 5.51M 68.92M 5.57M 5.45M 239M	2.6M 0 2.27M 2.1M 1.97M 3.69M 245M 3.71M 24.91M 9.65M 121M 9.76M 9.55M 419M
Net income	-16.69M -0 -14.55M -13.48M -12.61M -23.66M -1.57B -23.8M -160M -61.95M -775M -62.64M -61.29M -2.69B	-13.92M -0 -12.13M -11.24M -10.52M -19.73M -1.31B -19.85M -133M -51.66M -646M -52.23M -51.11M -2.24B
Net Debt	-	-